•
Dec 31, 2023
Curis Q4 2023 Earnings Report
Curis reported a net loss for Q4 2023, presented emavusertib data at ASH, and is expanding clinical sites.
Key Takeaways
Curis, Inc. reported its Q4 2023 financial results, featuring a net loss of $11.7 million, and provided a business update highlighting emavusertib data presented at ASH and expansion of clinical sites in the US and Europe. They expect their cash to last into 2025.
Emavusertib data presented at ASH showed 3 of 5 patients achieved CR in R/R PCNSL.
Expansion of clinical sites in US and Europe is in progress.
Curis expects its existing cash, cash equivalents and investments should enable its planned operations into 2025.
Management hosted a conference call on February 8, 2024, to discuss the business update and financial results.
Curis
Curis
Forward Guidance
Curis anticipates updated clinical data readouts in 2024.
Positive Outlook
- TakeAim Leukemia – updated clinical data from the on-going monotherapy study in the first half of 2024.
- TakeAim Lymphoma – updated clinical data from the on-going combination study of emavusertib with ibrutinib in the second half of 2024.
- Curis expects initial clinical data from the recently initiated triplet combination study of emavusertib with azacitidine and venetoclax to treat AML patients in the second half of 2024.